// App-Quantinova.ai

350 : Transferred Donor-Derived WT1-Specific CD8+ T-Cell Clones After Hematopoietic Cell Transplantation Mediate Antileukemic Activity and Can Establish Persistent Responses without Toxicity to Normal Tissues in High-Risk Leukemia Patients

Researchers

Presenter

  • Gunnar B. Ragnarsson

Principal Investigators

  • Hieu Nguyen

  • Jerald P. Radich

  • Cassian Yee

  • Philip Greenberg

  • Colette N Chaney

  • Jeff Pufnock

  • Tomas Schmitt

  • Natalie Duerkopp

  • Ilana Roberts

  • Galina Pogosov

  • William Ho

  • Merav Bar

Medical Centers

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Hematological malignancies

  • Graft-versus-host disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Chronic Myelogenous Leukemia

  • Acute lymphoblastic leukemia

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Breakpoint Cluster Region

  • C-C Motif Chemokine Receptor 7

  • Cluster of Differentiation 34

  • Cluster of differentiation 8A

  • Interleukin-2

  • Interleukin-21

  • L-selectin

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Recombinant Interleukin 21

  • Immunol

  • Florid

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved